Females with Epilepsy Show Menstrual Cycle-linked Alterations in Sensory Induced Plasticity
Abstract Introduction. Catamenial epilepsy describes menstrual cycle-linked exacerbation of seizure frequency and/or intensity. To investigate its neurophysiological mechanisms, we assessed visual long-term potentiation (LTP) across the menstrual cycle using EEG and photic stimulation. Oestradiol can enhance NMDA receptor-mediated excitation and facilitate LTP, whereas allopregnanolone, a progesterone metabolite, promotes GABAergic inhibition and suppresses LTP. Methods. We recruited 28 females with epilepsy and 25 controls (mean age: 27 ± 8.52; 30 ± 7.06 years, respectively). Twenty participants with epilepsy and all controls successfully completed the visual LTP task across three menstrual phases: mid-follicular, mid-luteal, and perimenstrual. Cycle phase was verified via blood samples, and session order was counterbalanced. Standard evoked-related potential (ERP) analysis was paired with generative modelling of thalamocortical circuits. Results. In controls, P2 potentiation, a positive-going component of the ERP, was enhanced by LTP induction during the mid-follicular phase compared to the perimenstrual phase (F(2, 144) =11.54, p = 0.004 FWE-c). In contrast, females with epilepsy exhibited greater P2 potentiation during the perimenstrual and mid-luteal phases than the mid-follicular phase (F(2,228) = 11.76, p = .003 FWE-c), with only two participants showing control-like pattern of peak mid-follicular potentiation. Computational modelling indicated loss of inhibitory control and breakthrough excitability during the perimenstrual and mid-luteal phases in epilepsy. Conclusion. Our findings reveal aberrant menstrual cycle modulation of sensory-induced plasticity in epilepsy, suggesting altered inhibitory gating as well as thalamocortical excitatory drive in the mid-luteal and perimenstrual phases. While GABAergic mechanisms are often emphasised in catamenial epilepsy, our results warrant considering altered excitatory mechanisms.
Authors
- Alexander D. Shaw (ORCID: https://orcid.org/0000-0001-5741-7526)
- Malak Alshakhouri (ORCID: https://orcid.org/0000-0002-2633-3159)
- Cynthia M. Sharpe (ORCID: https://orcid.org/0000-0002-6194-3307)
- Khalid Hamandi (ORCID: https://orcid.org/0000-0001-7116-262X)
- Rachael L. Sumner (ORCID: https://orcid.org/0000-0002-2652-4617)
- Peter Bergin (ORCID: https://orcid.org/0000-0003-0181-1959)
Institutions
- Cardiff and Vale University Health Board (GB)
- University of Auckland (NZ)
- University of Exeter (GB)
- Starship Children's Health (NZ)
- Health New Zealand (NZ)
- Cardiff University (GB)
Publication Details
- Journal
- Neuroendocrinology
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1159/nen/advag017
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Auckland Medical Research Foundation
- Maurice and Phyllis Paykel Trust